Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One vaccine to fight five types of meningitis? pfizer tests new combo shot in teens

NCT ID NCT04440176

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Pfizer study tested a new 5-in-1 vaccine (MenABCWY) that targets five types of meningococcal bacteria, which can cause serious infections like meningitis. The trial involved 309 healthy teens aged 11 to 14 and compared two different dosing schedules (shots 12 months apart vs. 36 months apart). Researchers measured how well the vaccine triggered an immune response and tracked any side effects. The goal is to find a safe and effective way to protect adolescents with fewer shots.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pentavalent meningococcal vaccine (MenABCWY)
What this could lead to
If successful, this could lead to a simpler vaccination schedule that protects against five types of meningococcal disease with fewer shots.
What could go wrong
This is a Phase 2b trial with only 309 participants, so results may not apply to everyone. The vaccine may not provide long-lasting protection or could have side effects not seen in this small study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

309 people

The number who actually took part.

Started

Jun 2020

Finished

Jan 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

11 to 14 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants 11 through \<15 years of age at the time of randomization. * Participants who have never received a prior dose of any meningococcal vaccine. Written confirmation of vaccination history must be obtained prior to randomization. * Available for the entire study period and can be reached by telephone. * Healthy participant as determined by medical history, physical examination, and judgement of the investigator. * Negative urine pregnancy test for all female participants; pregnancy test is not applicable to male participants. Exclusion Criteria: * A previous anaphylactic reaction to any vaccine or vaccine-related component. * Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection. * A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as participants with congenital or acquired defects in B-cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. * History of microbiologically proven disease caused by Neisseria meningitidis or Neisseria gonorrhoeae. * Significant neurological disorder or history of seizure (excluding simple febrile seizure). * Any neuroinflammatory or autoimmune condition, including, but no limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis. * Participants receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses. * Receipt of any blood products, including immunoglobulin, within 6 months before the first study vaccination. * Current use of systemic antibiotics with no foreseeable date of discontinuation prior to anticipated date of enrollment (first vaccination).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meningococcal vaccine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Meningococcal vaccine

Contacts and locations

Locations

  • AMR Clinical

    Mobile, Alabama, 36608, United States

  • AMR Clinical

    Roy, Utah, 84067, United States

  • AMR Clinical

    South Jordan, Utah, 84095, United States

  • Benchmark Research

    Fort Worth, Texas, 76135, United States

  • California Research Foundation

    San Diego, California, 92123, United States

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45206, United States

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

  • Coastal Carolina Research Center

    North Charleston, South Carolina, 29405, United States

  • Diagnostics Research Group

    San Antonio, Texas, 78229, United States

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah, 84109, United States

  • J. Lewis Research, Inc. / Foothill Family Clinic South

    Salt Lake City, Utah, 84121, United States

  • Nona Pediatric Center

    Orlando, Florida, 32829, United States

  • Ohio Pediatric Research Association Inc.

    Dayton, Ohio, 45414, United States

  • Pediatric Research of Charlottesville, LLC

    Charlottesville, Virginia, 22902, United States

  • Texas Health Resources

    Fort Worth, Texas, 76135, United States

  • Utah Valley Pediatrics - Timpanogos Office

    Orem, Utah, 84057, United States

  • Velocity Clinical Research, Norfolk

    Norfolk, Nebraska, 68701, United States

  • Wasatch Pediatrics, Cottonwood Office

    Murray, Utah, 84107, United States

  • Wee Care Pediatrics

    Kaysville, Utah, 84037, United States

  • Wee Care Pediatrics

    Syracuse, Utah, 84075, United States